09:41 AM EST, 12/19/2024 (MT Newswires) -- Vertex Pharmaceuticals ( VRTX ) said Thursday that its oral pain signal inhibitor suzetrigine met its primary endpoint in reducing pain in patients with lumbosacral radiculopathy in a phase 2 trial.

The company said that the suzetrigine arm demonstrated a statistically significant and clinically meaningful reduction in pain as measured on the numeric pain rating scale. At week 12, the suzetrigine arm showed a 2.02 point reduction from baseline while a placebo arm showed a 1.98 point reduction, Vertex said.

Suzetrigine was well tolerated, with secondary endpoints aligning with primary findings, Vertex Pharmaceuticals ( VRTX ) said.

Shares were down more than 10% in recent trading.

Price: 403.18, Change: -44.32, Percent Change: -9.90